In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Learning From Danish Leaders: Openness, Engagement And Balance

Five Danish Biopharma Leaders Reflect On The Benefits And Limitations Of Their Country's Approach To Management

Executive Summary

Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.

You may also be interested in...



Fostering a Culture of Innovation, From Evolutionary To Revolutionary

Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.

Radical Honesty Is Part Of The Secret To Apellis's Success

On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.

AbbVie Strengthens Evidence For Rinvoq In Crohn's

Over 10 datasets presented at Digestive Disease Week strengthen the case that clinicians should view AbbVie’s selective JAK inhibitor Rinvoq as a powerful addition to their clinical toolbox for moderate-to-severe Crohn’s disease patients. However, safety concerns will keep it as second-line treatment in the US after its likely label expansion this month.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel